The DEPRE’5 study: pragmatic, multicentre, five-arm, parallel-group randomised controlled trial with blinded assessment to compare treatment strategies in major depression after a failed selective serotonin reuptake inhibitor treatment

Patients with MDD and insufficient response to SSRIs would benefit from any other second-line strategy aside from dose optimisation. With limited statistical power, switching to venlafaxine and adding psychotherapy yielded the most consistent results in the DEPRE'5 study.

Authors

Institutions

Publication Details

Journal
The British Journal of Psychiatry
Published
2025-06-18
DOI
https://doi.org/10.1192/bjp.2025.13
Citations
2
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
2.79

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The DEPRE’5 study: pragmatic, multicentre, five-arm, parallel-group randomised controlled trial with blinded assessment to compare treatment strategies in major depression after a failed selective serotonin reuptake inhibitor treatment

Judith Usall, Dolors Puigdemont, Irene S. Leal, Javier Garcı́a-Campayo et al.
2 citations
The British Journal of Psychiatry
Treatment of Major Depression
2.79
article

The DEPRE’5 study: pragmatic, multicentre, five-arm, parallel-group randomised controlled trial with blinded assessment to compare treatment strategies in major depression after a failed selective serotonin reuptake inhibitor treatment

Judith Usall, Dolors Puigdemont, Irene S. Leal, Javier Garcı́a-Campayo, Mikel Urretavizcaya, Lorena García‐Fernández, Roberto Rodríguez–Jiménez, Javier de Diego-Adeliño, Raquel López‐Carrilero, Ana González‐Pinto, Ángel L. Montejo, Miguel Ángel Álvarez-Mon, María J. Escartí, José Manuel García Montes, Víctor Pérez, Matilde Elices, Eduardo J. Aguilar, Francesc Colom, Elena Luján, José Luís Ayuso‐Mateos, María Cabello, Jordi Blanch, Ascensión Gallego-Nogueras, Agurtzane Ortiz-Jauregui
article en
2 citations

Abstract

Patients with MDD and insufficient response to SSRIs would benefit from any other second-line strategy aside from dose optimisation. With limited statistical power, switching to venlafaxine and adding psychotherapy yielded the most consistent results in the DEPRE'5 study.

The British Journal of PsychiatryVol. 227(5)
Universitat de Miguel Hernández d'Elx (ES), Universidad Complutense de Madrid (ES), Universitat Autònoma de Barcelona (ES), Universitat de València (ES), Universitat Pompeu Fabra (ES), Universidad de Alcalá (ES), Universidad de Zaragoza (ES), Instituto de Salud Carlos III (ES), Hospital de Sant Pau (ES), Bellvitge University Hospital (ES), University of Cebu (PH), Research Institute Hospital 12 de Octubre (ES), Institut d'Investigació Biomédica de Bellvitge (ES), Hospital Universitari de Santa Maria (ES), Centro de Investigación Biomédica en Red de Salud Mental (ES), Hospital Universitari Sant Joan D'Alacant (ES), Hospital Clínico Universitario de Valencia (ES), Hospital San Juan de Dios (VE), Hospital Universitario 12 De Octubre (ES), Red de Investigación en Actividades Preventivas y Promoción de la Salud (ES), Hospital Universitario Araba (ES), Hospital Universitario Miguel Servet (ES), Hospital Clínic de Barcelona (ES), Instituto Nacional de Salud (PE), Hospital Universitario del Sureste (ES), Instituto Ramón y Cajal de Investigación Sanitaria (ES), Parc Sanitari Sant Joan de Déu (ES), Hospital Universitario de La Princesa (ES), Hospital Del Mar (ES), Instituto de Investigación Biomédica de Salamanca (ES), Instituto de Investigación Sanitaria Aragón (ES), Instituto de Investigación Sanitaria de Santiago (ES), Hospital del Mar Research Institute (ES), Hospital Universitario Ramón y Cajal (ES), Hospital Universitario Infanta Leonor (ES), Institut de Recerca Sant Pau (ES), Universidad Autónoma de Madrid (ES), Universitat de Barcelona (ES)
Amgen, Pfizer, Gilead Sciences, ViiV Healthcare, University of Cambridge, Generalitat de Catalunya, Eusko Jaurlaritza, Ministerio de Ciencia e Innovación, Centro de Investigación Biomédica en Red de Salud Mental, Servier, H. Lundbeck A/S, Neuraxpharm, Idorsia Pharmaceuticals, Instituto de Salud Carlos III, European Regional Development Fund
Good health and well-being
Openalex Percentile: Top 10%
Treatment of Major Depression
2.79
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.